ekonominyheter

TranslateRSSMobil
Trial Results Not Expected to Hurt Merck's Vytorin, Zetia

Trial Results Not Expected to Hurt Merck's Vytorin, Zetia

Wall Street Journal 10/11 15:26

Merck & Co. has determined there is no need to write down the value of blockbuster cholesterol drugs Vytorin and Zetia, suggesting the results of a long-running clinical trial results won?t hurt their value.

Till artikeln

Ekonomi Nyheter .se - Innehåll

 

 

 

 

DMCA.com Protection Status